Citi analyst Yigal Nochomovitz lowered the firm’s price target on Shattuck Labs to $8 from $9 and keeps a Buy rating on the shares. The analyst updated biotechnology models to reflect the Q2 reports.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STTK:
- Shattuck Labs: Cash equivalents and investments will be sufficient into 2026
- Shattuck Labs reports Q2 EPS (42c), consensus (41c)
- Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference
- Shattuck Labs announces addition to Russell 2000, Russell 3000 Indexes
- Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes